BioNxt Solutions Inc. (CSE:BNXT)
Canada · Delayed Price · Currency is CAD 0.4100
-0.0100 (-2.38%)
May 21, 2026, 10:43 AM EST
BioNxt Solutions Revenue
BioNxt Solutions had revenue of -11.26K CAD in the quarter ending December 31, 2025.
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
20
Market Cap
53.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 26.99K | -345.26K | -92.75% |
| Dec 31, 2023 | 372.25K | 74.81K | 25.15% |
| Dec 31, 2022 | 297.44K | 10.94K | 3.82% |
| Dec 31, 2021 | 286.50K | -59.16K | -17.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| iAnthus Capital Holdings | 193.99M |
| Planet 13 Holdings | 134.62M |
| Decibel Cannabis Company | 112.72M |
| Vext Science | 70.43M |
| Charlotte's Web Holdings | 68.11M |
| Leef Brands | 48.53M |
| C21 Investments | 45.62M |
| MediPharm Labs | 43.28M |
BioNxt Solutions News
- 2 days ago - BioNxt Advances Semaglutide ODF Program into Active Pharmaceutical Development - Accesswire
- 23 days ago - BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum - Accesswire
- 5 weeks ago - BioNxt Initiates GMP Manufacturing of Clinical-Grade Sublingual Cladribine Film Targeting Multiple Sclerosis (MS) - Accesswire
- 6 weeks ago - BioNxt Secures Unitary European Patent for Sublingual Cladribine ODF Platform Across 18 Countries - Accesswire
- 7 weeks ago - BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy - Accesswire
- 2 months ago - BioNxt Enters Commercialization Phase with Global Patent Protection and U.S. Fast Track Strategy for Sublingual Drug Delivery Platform - Accesswire
- 2 months ago - BioNxt Signs Strategic Agreement for Eurasian Commercialization Following Cladribine ODF Patent Grant in Eurasia and Europe - Accesswire
- 3 months ago - BioNxt Announces Closing of Shares for Debt Settlement - Accesswire